Stock chart
Analyses on Opko (8)
- May 4, 2026
- April 30, 2026April 30, 2026
- Follow-up
BioReference after the first clean quarter: is the cost reset enough?
BioReference has reached the stage where cost actions are clearly reducing the operating loss, but they have not yet proven durable profitability. Gross margin rate improved and the operating loss narrowed, while continuing revenue declined and gross profit dollars fell.
- Follow-up
Follow-up to OPKO: did the first quarter change the economics of pipeline funding?
The first quarter did not change OPKO's pipeline funding economics. It showed lower BARDA revenue, thinner R&D offsets, and higher earlier-stage program spending while Regeneron and Entera still need to move from validation to actual cost coverage.
OPKO in the first quarter: a smaller business, a narrower loss, and still no self-funding model
OPKO opened 2026 as a smaller and more efficient business, with a narrower operating loss and lower negative operating cash flow, but still without proof that the new core can fund the pipeline, debt, and buyback from ongoing operations.
